Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297410> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4286297410 endingPage "4592" @default.
- W4286297410 startingPage "4592" @default.
- W4286297410 abstract "4592 Background: In Bacillus Calmette-Guérin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC), radical cystectomy is the standard of care. For patients unwilling or unable to undergo cystectomy, alternative intravesical therapies are currently being investigated to minimize the risk of recurrence and progression. Chemohyperthermia by HIVEC (Hyperthermic-Intra-Vesical Chemotherapy) is a therapeutic option in BCG-refractory patients. The objective of our study was to evaluate the 2-year oncological results of HIVEC in BCG-refractory patients. Methods: Between June 2016 and September 2021, patients treated with HIVEC (6 weekly instillations) for BCG-refractory NMIBC were prospectively included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it. The primary endpoint was 1-year recurrence-free survival (RFS) rate. Secondary endpoints were 6-month complete response rate for Cis, 1-year overall and cancer-specific survival rates and bladder preservation rate. Results: Seventy patients, mean age 70 [42-89] years, were treated consecutively. After a mean follow-up of 20.9 months, 32 patients recurred (mean time of 10.6 months) and 7 patients finally had a cystectomy. The recurrence-free survival rate was 53.1% at 1 year and 20.5% at 2 years. Six patients progressed to a muscle-invasive disease, after a mean delay of 6.7 months. Four of them experienced metastatic progression and died from bladder cancer. Cancer-specific and overall survival rates were 95.1% and 92.9% at 1 year, and 87.5% and 77.8% at 2 years. The bladder preservation rate was 90%. For patients with Cis (34% of the entire series), the 6-month complete response rate was 75%. The presence of Cis was not a predictive factor of response to HIVEC. Tolerance was excellent with 38.2% grade 1-2 adverse events and no grade 3-4 adverse events. Conclusions: Chemohyperthermia using the HIVEC device achieved a RFS rate of 53.1% at 1 year and enabled a bladder preservation rate of 90%. While cystectomy remains the standard of care, HIVEC may be discussed cautiously for patients who are not eligible for surgery and well informed of the risk of progression to muscle-invasive disease." @default.
- W4286297410 created "2022-07-21" @default.
- W4286297410 creator A5001182866 @default.
- W4286297410 creator A5003269057 @default.
- W4286297410 creator A5009497129 @default.
- W4286297410 creator A5014533663 @default.
- W4286297410 creator A5017973944 @default.
- W4286297410 creator A5021061571 @default.
- W4286297410 creator A5027353243 @default.
- W4286297410 creator A5028221013 @default.
- W4286297410 creator A5051081121 @default.
- W4286297410 creator A5072465879 @default.
- W4286297410 creator A5074336646 @default.
- W4286297410 date "2022-06-01" @default.
- W4286297410 modified "2023-10-16" @default.
- W4286297410 title "Efficacy of hyperthermic-intra-vesical chemotherapy in patients with BCG-refractory nonmuscle-invasive bladder cancer." @default.
- W4286297410 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4592" @default.
- W4286297410 hasPublicationYear "2022" @default.
- W4286297410 type Work @default.
- W4286297410 citedByCount "0" @default.
- W4286297410 crossrefType "journal-article" @default.
- W4286297410 hasAuthorship W4286297410A5001182866 @default.
- W4286297410 hasAuthorship W4286297410A5003269057 @default.
- W4286297410 hasAuthorship W4286297410A5009497129 @default.
- W4286297410 hasAuthorship W4286297410A5014533663 @default.
- W4286297410 hasAuthorship W4286297410A5017973944 @default.
- W4286297410 hasAuthorship W4286297410A5021061571 @default.
- W4286297410 hasAuthorship W4286297410A5027353243 @default.
- W4286297410 hasAuthorship W4286297410A5028221013 @default.
- W4286297410 hasAuthorship W4286297410A5051081121 @default.
- W4286297410 hasAuthorship W4286297410A5072465879 @default.
- W4286297410 hasAuthorship W4286297410A5074336646 @default.
- W4286297410 hasConcept C121332964 @default.
- W4286297410 hasConcept C121608353 @default.
- W4286297410 hasConcept C126322002 @default.
- W4286297410 hasConcept C126894567 @default.
- W4286297410 hasConcept C141071460 @default.
- W4286297410 hasConcept C142424586 @default.
- W4286297410 hasConcept C168563851 @default.
- W4286297410 hasConcept C203092338 @default.
- W4286297410 hasConcept C2775910329 @default.
- W4286297410 hasConcept C2776283816 @default.
- W4286297410 hasConcept C2776694085 @default.
- W4286297410 hasConcept C2780352672 @default.
- W4286297410 hasConcept C71924100 @default.
- W4286297410 hasConcept C87355193 @default.
- W4286297410 hasConceptScore W4286297410C121332964 @default.
- W4286297410 hasConceptScore W4286297410C121608353 @default.
- W4286297410 hasConceptScore W4286297410C126322002 @default.
- W4286297410 hasConceptScore W4286297410C126894567 @default.
- W4286297410 hasConceptScore W4286297410C141071460 @default.
- W4286297410 hasConceptScore W4286297410C142424586 @default.
- W4286297410 hasConceptScore W4286297410C168563851 @default.
- W4286297410 hasConceptScore W4286297410C203092338 @default.
- W4286297410 hasConceptScore W4286297410C2775910329 @default.
- W4286297410 hasConceptScore W4286297410C2776283816 @default.
- W4286297410 hasConceptScore W4286297410C2776694085 @default.
- W4286297410 hasConceptScore W4286297410C2780352672 @default.
- W4286297410 hasConceptScore W4286297410C71924100 @default.
- W4286297410 hasConceptScore W4286297410C87355193 @default.
- W4286297410 hasIssue "16_suppl" @default.
- W4286297410 hasLocation W42862974101 @default.
- W4286297410 hasOpenAccess W4286297410 @default.
- W4286297410 hasPrimaryLocation W42862974101 @default.
- W4286297410 hasRelatedWork W2022837219 @default.
- W4286297410 hasRelatedWork W2073348951 @default.
- W4286297410 hasRelatedWork W2120921122 @default.
- W4286297410 hasRelatedWork W2328067422 @default.
- W4286297410 hasRelatedWork W2415455286 @default.
- W4286297410 hasRelatedWork W2461580845 @default.
- W4286297410 hasRelatedWork W2599552653 @default.
- W4286297410 hasRelatedWork W2793829872 @default.
- W4286297410 hasRelatedWork W3031752735 @default.
- W4286297410 hasRelatedWork W3129080622 @default.
- W4286297410 hasVolume "40" @default.
- W4286297410 isParatext "false" @default.
- W4286297410 isRetracted "false" @default.
- W4286297410 workType "article" @default.